ZIOPHARM Oncology (ZIOP) Reports Palifosfamide Hits PFS Events in Phase 3
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the IDMC (Independent Data Monitoring Committee). The Company will announce topline results from this trial during the last week of March 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ziopharm Oncology (ZIOP) Completes Enrollment in Second Patient Cohort of Phase 1 Study of Ad-RTS-hIL-12
- Marinus (MRNS) Plans Conference Call to Reports Results From Phase 2 Study of Ganaxolone in Children with Fragile X
- Sequenom (SQNM) Disappointed Supreme Court Denied Petition Requesting Review of Decision on '540 Patent
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!